Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q1 2015 · 10-Q
Revenue—
Net Income-$4.55M-$4.55MN/M vs Q1 2014 EPS Diluted-$0.19-$0.19N/M vs Q1 2014 Operating Income-$1,270,800N/M Operating Cash Flow-$1,011,800N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
ended Jun 30, 2014 · filed Aug 12, 2014 · 43 d after period end